Question · Q4 2025
Mike Halloran asked about the disconnect between IDEX's strong order momentum and its conversion to revenue, particularly with the introduction of longer-cycle applications, and when this dynamic is expected to normalize. He also requested an update on life sciences trends, the outlook for the year, and how client expectations correlate with IDEX's projections.
Answer
Eric Ashleman, President and CEO of IDEX, explained that the revenue flow dynamic includes traditional Q1 softness in FMT due to weather (water and agriculture franchises) and a newer HST component. Larger orders, particularly in materials processing technologies, captured late in Q4, have longer lead times, pushing revenue conversion into Q2. He noted that assurance levels are significantly higher this year, especially in HST, due to a substantial backlog build. For life sciences, Eric Ashleman described 2025 as stable, low single-digit growth, driven by pharma applications but pressured by academic research, with the Q4 government shutdown adding uncertainty. He anticipates continued low single-digit growth, with ongoing innovation and new product releases, while monitoring factors like NIH funding and China-related dynamics.
Ask follow-up questions
Fintool can predict
IEX's earnings beat/miss a week before the call